ALNA
Allena Pharma
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 46.12M; Volume: 426.32K; AvgVol 3m: 1.81M; Beta: –;
Cost estimate:
P/E: –; EPS: -1.62; EPS growth quarter/prev quarter: 51.90%;
EPS growth this year: -24.20%; EPS growth past 5 years: ;
EPS ttm: -1.62;
P/S: ; P/B: 2.43; P/Cashflow: 2.54; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -121.00%; ROE – return on equity: -219.60%; LT Debt/Equity: 0.22; Total Debt/Equity: 0.43;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 10.16%; Insider Transactions:0.00%;
Institutional Ownership: 45.60%; Institutional Transactions: 12.55%;
Data update: 07.10.2020.